Kardigan, Inc. (NASDAQ:KARD - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Kardigan in a research note issued on Thursday, November 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($3.70) per share for the year, up from their prior estimate of ($4.01). HC Wainwright currently has a "Buy" rating and a $42.00 target price on the stock. The consensus estimate for Kardigan's current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for Kardigan's Q4 2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.92) EPS, Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.84) EPS, FY2027 earnings at ($3.47) EPS, FY2028 earnings at ($3.70) EPS, FY2029 earnings at ($3.92) EPS and FY2030 earnings at ($0.61) EPS.
KARD has been the topic of several other reports. Wall Street Zen lowered Kardigan from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. UBS Group assumed coverage on Kardigan in a report on Monday, October 12th. They set a "buy" rating and a $25.00 price objective on the stock. Robert W. Baird initiated coverage on Kardigan in a research note on Wednesday, October 21st. They issued an "outperform" rating and a $43.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Kardigan in a research report on Thursday, October 29th. They set an "overweight" rating and a $50.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price target on shares of Kardigan from $51.00 to $46.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 25th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Kardigan presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.00.
Get Our Latest Report on KARD
Kardigan Stock Performance
Shares of KARD stock opened at $13.82 on Monday. The business's 50-day moving average price is $15.14. Kardigan has a 12-month low of $12.23 and a 12-month high of $27.00. The company has a market capitalization of $1.29 billion and a price-to-earnings ratio of -4.80.
Kardigan (NASDAQ:KARD - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.16.
Institutional Investors Weigh In On Kardigan
A number of hedge funds and other institutional investors have recently modified their holdings of KARD. Jupiter Topco LLC bought a new position in Kardigan during the 2nd quarter worth approximately $17,715,000. Montanova Capital LLC purchased a new position in Kardigan in the 2nd quarter worth approximately $9,540,000. Bank of New York Mellon Corp purchased a new position in Kardigan in the 2nd quarter worth approximately $9,010,000. Braidwell LP bought a new stake in Kardigan in the second quarter valued at approximately $7,155,000. Finally, State Street Corp bought a new stake in Kardigan in the third quarter valued at approximately $6,721,000.
Key Kardigan News
Investors following KARD have been watching these news items:
- Positive Sentiment: HC Wainwright narrowed its projected losses for FY2026, FY2028, FY2029 and FY2030. For example, its FY2026 EPS estimate improved to ($3.70) from ($4.01), and its FY2030 estimate to ($0.61) from ($0.79). The analyst also maintained a $42 target and Buy rating. Kardigan analyst estimate revisions
- Negative Sentiment: The firm lowered its estimates for each quarter of 2027 and for FY2027, now projecting a full-year loss of ($3.47) per share versus its prior estimate of ($3.29). The increased expected losses could weigh on sentiment, despite the longer-term improvements. Kardigan analyst estimate revisions
About Kardigan
(
Get Free Report)
Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company's activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kardigan, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kardigan wasn't on the list.
While Kardigan currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.